{
    "clinical_study": {
        "@rank": "55433", 
        "acronym": "GELATIN", 
        "arm_group": {
            "arm_group_label": "Balloon Assisted Coiling", 
            "arm_group_type": "Experimental", 
            "description": "Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter."
        }, 
        "brief_summary": {
            "textblock": "The objective of the GELATIN registry is to prospectively evaluate intracranial aneurysm\n      occlusion and retreatment rates as well as adverse event rates in patients undergoing\n      balloon-assisted coiling using the MicroVention Scepter Occlusion Balloon Catheter and\n      second-generation MicroVention hydrogel coils for treatment of previously treated or\n      untreated ruptured and unruptured intracranial aneurysms."
        }, 
        "brief_title": "Hydrogel Balloon Assisted Intracranial Aneurysm Coiling Registry", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Intracranial Aneurysms", 
            "Aneurysm", 
            "Brain Aneurysm"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Aneurysm", 
                "Intracranial Aneurysm"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a prospective, single arm, single center study of patients with ruptured or\n      unruptured saccular aneurysms that are embolized using MicroVention second-generation\n      hydrogel coils and undergo balloon remodeling with the MicroVention Scepter Occlusion\n      Balloon Catheter.  Data for each patient will be collected 6 \u00b1 3 months post-procedure for\n      the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient is 18-80 years of age.\n\n          -  Patient has a documented, previously treated or untreated saccular intracranial\n             aneurysm, 4- 20 mm unruptured or ruptured, suitable for treatment with balloon\n             assisted coil embolization.\n\n          -  Target aneurysm has a neck \u22654mm or the largest diameter to neck ratio of 2 or less.\n\n          -  Patient has a Hunt and Hess Score of 3 or less.\n\n          -  Patient has a premorbid mRS of 3 or less.\n\n          -  Patient or patient's legally authorized representative has provided written informed\n             consent.\n\n          -  Patient is willing to and can comply with study follow-up requirements.\n\n        Exclusion Criteria:\n\n          -  Inability to obtain informed consent.\n\n          -  Patient is <18 or >80 years of age.\n\n          -  Target aneurysm is dissecting, fusiform, mycotic, or arteriovenous\n             malformation-related.\n\n          -  Aneurysm that was treated previously with stent-assisted coiling.\n\n          -  Implantation of the stent after the balloon-assisted coiling or combined stent and\n             balloon assisted coiling.\n\n          -  Target aneurysm is deemed unsuitable for balloon-assisted coiling by the treating\n             physician prior to the procedure.\n\n          -  Target aneurysm will be treated with a total coil length comprised of less than 80%\n             second generation MicroVention Hydrogel Coils.\n\n          -  Balloon-assisted coiling will be performed using a balloon catheter other than the\n             MicroVention Scepter balloon (Scepter C, Scepter XC, any future Scepter\n             configurations).\n\n          -  Patients in which the target aneurysm is planned not to be coiled in one procedure\n             (i.e. staged procedure).\n\n          -  Patients with more than one aneurysm that requires treatment.\n             (However, a second small low risk aneurysm that does not require therapy may be\n             allowed.)\n\n          -  Patients with a life expectancy of \u2264 9 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02037932", 
            "org_study_id": "00021229"
        }, 
        "intervention": {
            "arm_group_label": "Balloon Assisted Coiling", 
            "description": "Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.", 
            "intervention_name": "Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.", 
            "intervention_type": "Device", 
            "other_name": [
                "MicroVention hydrogel coils", 
                "MicroVention Scepter C", 
                "MicroVention Scepter XC"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Aneurysm", 
            "Brain Aneurysm"
        ], 
        "lastchanged_date": "January 14, 2014", 
        "location": {
            "contact": {
                "last_name": "Osama O Zaidat, MD, MS", 
                "phone": "414-805-5219"
            }, 
            "facility": {
                "address": {
                    "city": "Milwaukee", 
                    "country": "United States", 
                    "state": "Wisconsin", 
                    "zip": "53226"
                }, 
                "name": "Medical College of Wisconsin"
            }, 
            "investigator": [
                {
                    "last_name": "Osama O Zaidat, MD, MS", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Brian-Fred Fitzsimmons, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "John Lynch, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Marc Lazarro, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Hydrogel Balloon Assisted Intracranial Aneurysm Coiling Registry", 
        "overall_contact": {
            "email": "acastonguay@mcw.edu", 
            "last_name": "Alicia C Castonguay, PhD", 
            "phone": "414-805-5439"
        }, 
        "overall_official": {
            "affiliation": "Medical College of Wisconsin", 
            "last_name": "Osama O Zaidat, MD, MS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Aneurysm recurrence rate", 
            "safety_issue": "No", 
            "time_frame": "3-9 month follow-up"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02037932"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical College of Wisconsin", 
            "investigator_full_name": "Osama Zaidat, MD, MSc", 
            "investigator_title": "Professor of Neurology, Neurosurgery, & Radiology", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Angiographic occlusion of the aneurysm will be adjudicated using immediate post-procedure and 3-9 month follow-up angiography.", 
                "measure": "Occlusion Rate", 
                "safety_issue": "No", 
                "time_frame": "At immediate post-procedure (Day 1) and 3-9 month follow-up"
            }, 
            {
                "measure": "Number of coils used", 
                "safety_issue": "No", 
                "time_frame": "At end of study procedure (Day 1)"
            }, 
            {
                "measure": "Total coil length used", 
                "safety_issue": "No", 
                "time_frame": "At immediate post-procedure (Day 1)"
            }, 
            {
                "measure": "Aneurysm re-treatment rate", 
                "safety_issue": "No", 
                "time_frame": "3-9 month follow-up"
            }, 
            {
                "description": "Aneurysm Bleed and Re-bleed Rate will be assessed and recorded at the 3-9 month follow-up.", 
                "measure": "Aneurysm Bleed and Re-bleed Rate", 
                "safety_issue": "Yes", 
                "time_frame": "3-9 month follow-up"
            }, 
            {
                "description": "Total time of fluoroscopic exposure will be captured from the initial recording of the road map to the final angiogram after completion of the coil embolization procedure.", 
                "measure": "Time of fluoroscopic exposure", 
                "safety_issue": "Yes", 
                "time_frame": "At immediate post-procedure (Day 1)"
            }, 
            {
                "description": "Modified Rankin score will be recorded at baseline, hospital discharge, and during the 3-9 month follow-up.", 
                "measure": "Modified Rankin Score", 
                "safety_issue": "No", 
                "time_frame": "At baseline (Day 1) and hospital discharge (Day 3) and 3-9 month follow-up"
            }, 
            {
                "description": "Procedural and post-procedural serious adverse events related to the device and/or procedure will be captured and recorded at the end of the procedure and until the patient has completed the 3-9 month follow-up.", 
                "measure": "Device-related serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From the study procedure (Day 1) until 3-9 month follow up"
            }
        ], 
        "source": "Medical College of Wisconsin", 
        "sponsors": {
            "collaborator": {
                "agency": "Microvention-Terumo, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Osama Zaidat, MD, MSc", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}